Recognizing the need for objective markers of brain injury, researchers have dedicated extensive efforts to developing concussion biomarkers.
Starting eslicarbazepine acetate (ESL) at 400 mg daily may result in fewer adverse effects than starting at 800 mg for most patients with partial onset seizures.
What are the symptoms of cluster headache? Which treatments have proven to be beneficial in relieving the pain of temporomandibular joint disorder? Those questions and more in this quiz.
Findings from a study in Neurology suggest that caffeine may be a biomarker for PD, which could represent a breakthrough for diagnosing PD using a simple blood test.
Teens survivors of terror attacks like mass shootings are 3 to 4 times more likely to suffer from frequent migraines than those who have not endured such experiences.
Intravenous alteplase (tPA) is the standard of care for acute ischemic stroke, if it can be given within 3-4.5 hours after stroke onset. Dr. Wilner reviews some important facts about intracranial hemorrhage after the use of intravenous alterpase.
Treatment-induced neuropathy of diabetes, also called insulin neuritis, may be more common than previously thought.
What are the direct costs and indirect costs of cluster headache in the US? Here's what the first study of this issue found.
Researchers conducted a retrospective analysis of patients with acute stroke and evaluated the effect of infection during the hospitalization period.
Sodium oxybate, a drug used to treat narcolepsy, may improve excessive daytime sleep and sleep disturbances in patients with Parkinson disease.
On the challenges of treating progressive multifocal leukoencephalopathy in MS patients.
These technologies show promise in predicting dementia years before clinical symptoms develop; diagnosing concussion and other brain injuries; and more.
Differential diagnosis and treatment of mitochondrial encephalomyopathy lactic acidosis and stroke-like syndrome.
There has been long-running controversy regarding the association between statins and PD risk. Two studies with conflicting results are examined here.
Findings from a new meta-analysis suggest these medications may be most effective in improving cognition in Alzheimer disease.